Bayer’s Post-Ruling Rally Hits a Bumpy Patch as Fitch and Legal Details Dampen Euphoria

Bayer shares took a breather on Wednesday, sliding 3.25% to €47.56 according to one data vendor, while another reading put the close at €47.86, down 2.64%. The pullback — the sharpest in recent weeks — snaps a blistering run that had lifted the stock by between 31% and 32% over the past 30 days, depending on the metric used. Yet the decline is less a verdict on Bayer’s legal progress and more a reflection of two hard truths: the Supreme Court victory last month is not a clean sweep, and the company’s balance sheet remains under scrutiny.

The landmark ruling on June 25 in Monsanto v. Durnell established that federal pesticide-labeling preempts state-level failure-to-warn claims, a decision that could render thousands of glyphosate lawsuits unviable. But the euphoria that pushed shares to a 52-week high of €53.86 on July 3 has faded as the market digests the finer points. Roughly 4,000 cases remain pending at the federal level, and a district judge in San Francisco — one who has previously questioned Bayer’s settlement framework — is now tasked with determining how broadly the ruling applies. CEO Bill Anderson acknowledged the uncertainty, saying the decision together with a February 2026 class settlement can “significantly contain” litigation, stopping short of declaring the matter resolved.

Adding to the cautious tone, Fitch affirmed Bayer’s “BBB” credit rating on Wednesday but kept the outlook negative, singling out the company’s persistent debt load. The timing was awkward: Bayer enters a quiet period before its half-year report on August 4, so management cannot publicly counter the rating agency’s skepticism. Fitch’s stance underscores the gap between the legal relief and the financial reality that still stares the group in the face. Operative cash flow in the second quarter will be a key test — a miss could push borrowing costs higher and renew pressure on the stock.

Should investors sell immediately? Or is it worth buying Bayer?

The technical picture tells a similar story of a rally that simply got ahead of itself. Even after Wednesday’s dip, the shares trade 25.15% above their 200-day moving average and 16.49% above the 50-day line (25.94% and 17.21% by alternative calculations). Such stretched readings rarely persist without consolidation. The RSI, which had been in overbought territory, has receded to a neutral 57.6–58.8, suggesting the air is clearing without triggering panic. The weekly performance shows a decline of 5.56% (or 4.96% by other data), confirming a pause rather than a reversal.

For bulls, the long-term trend remains intact. Over the past twelve months, Bayer has surged roughly 75% — a near-doubling from its 52-week low of €25.09. The shift from being a DAX value trap to a €49.24 billion market-cap heavyweight is remarkable. Support at the 50-day average around €40.83 is well below current levels, giving the stock room to consolidate without breaking the broader uptrend.

Bearish voices point to the asymmetry between legal headlines and cash-flow fundamentals. The 11.70% gap from the recent high of €53.86 to Wednesday’s close leaves the stock vulnerable if profit-taking accelerates. Speculative buyers who piled in after the Supreme Court decision may now lock in gains, and a break below short-term moving averages could trigger further selling. The critical psychological level of €45.00 is suddenly within sight should the consolidation deepen.

August brings two decisive events. On August 4, Bayer will release its half-year results, testing whether the Crop Science and Pharmaceuticals divisions can validate management’s optimistic guidance. Then, on August 19, the final fairness hearing on the $7.25 billion class settlement takes place in a U.S. court. If the judge approves the accord, it would remove a major overhang and potentially allow the stock to rerate higher. Until then, Bayer remains caught between the cautious language of rating agencies and the unfinished business of its legal legacy.

Ad

Bayer Stock: New Analysis - 15 July

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69775166 |